{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T14:06:12Z","timestamp":1768831572919,"version":"3.49.0"},"reference-count":56,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T00:00:00Z","timestamp":1620086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","award":["RGPIN-2018-05514"],"award-info":[{"award-number":["RGPIN-2018-05514"]}],"id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Inhibition of the RAF-MEK1\/2-ERK signaling pathway is an ideal strategy for treating cancers with NRAS or BRAF mutations. However, the development of resistance due to incomplete inhibition of the pathway and activation of compensatory cell proliferation pathways is a major impediment of the targeted therapy. The anthrax lethal toxin (LT), which cleaves and inactivates MEKs, is a modifiable biomolecule that can be delivered selectively to tumor cells and potently kills various tumor cells. However, resistance to LT and the mechanism involved are yet to be explored. Here, we show that LT, through inhibiting MEK1\/2-ERK activation, inhibits the proliferation of cancer cells with NRAS\/BRAF mutations. Among them, the human colorectal tumor HT-29 and murine melanoma B16-BL6 cells developed resistance to LT in 2 to 3 days of treatment. These resistant cells activated AKT through a histone deacetylase (HDAC) 8-dependent pathway. Using an Affymetrix microarray, followed by qPCR validation, we identified that the differential expression of the phospholipase C-\u03b21 (PLCB1) and squamous cell carcinoma-1 (DESC1) played an important role in HDAC8-mediated AKT activation and resistance to MEK1\/2-ERK inhibition. By using inhibitors, small interference RNAs and\/or expression vectors, we found that the inhibition of HDAC8 suppressed PLCB1 expression and induced DESC1 expression in the resistant cells, which led to the inhibition of AKT and re-sensitization to LT and MEK1\/2 inhibition. These results suggest that targeting PLCB1 and DESC1 is a novel strategy for inhibiting the resistance to MEK1\/2 inhibition.<\/jats:p>","DOI":"10.3390\/cells10051101","type":"journal-article","created":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T11:06:01Z","timestamp":1620212761000},"page":"1101","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["HDAC8 Activates AKT through Upregulating PLCB1 and Suppressing DESC1 Expression in MEK1\/2 Inhibition-Resistant Cells"],"prefix":"10.3390","volume":"10","author":[{"given":"Soon-Duck","family":"Ha","sequence":"first","affiliation":[{"name":"Department of Microbiology &amp; Immunology, Schulich School of Medicine &amp; Dentistry, University of Western Ontario, London, ON N6G 2V4, Canada"},{"name":"Department of Biochemistry, Schulich School of Medicine &amp; Dentistry, University of Western Ontario, London, ON N6G 2V4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naomi","family":"Lewin","sequence":"additional","affiliation":[{"name":"Department of Microbiology &amp; Immunology, Schulich School of Medicine &amp; Dentistry, University of Western Ontario, London, ON N6G 2V4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shawn S. C.","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Schulich School of Medicine &amp; Dentistry, University of Western Ontario, London, ON N6G 2V4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0282-6661","authenticated-orcid":false,"given":"Sung-Ouk","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Microbiology &amp; Immunology, Schulich School of Medicine &amp; Dentistry, University of Western Ontario, London, ON N6G 2V4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,5,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1517\/14728222.2011.645805","article-title":"Targeting the mapk-ras-raf signaling pathway in cancer therapy","volume":"16","author":"Santarpia","year":"2012","journal-title":"Expert. Opin. Ther. Targets"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Lee, S., Rauch, J., and Kolch, W. (2020). Targeting mapk signaling in cancer: Mechanisms of drug resistance and sensitivity. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21031102"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Proietti, I., Skroza, N., Bernardini, N., Tolino, E., Balduzzi, V., Marchesiello, A., Michelini, S., Volpe, S., Mambrin, A., and Mangino, G. (2020). Mechanisms of acquired braf inhibitor resistance in melanoma: A systematic review. Cancers, 12.","DOI":"10.3390\/cancers12102801"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1158\/1078-0432.CCR-13-1610","article-title":"Molecular pathways: Resistance to kinase inhibitors and implications for therapeutic strategies","volume":"20","author":"Lovly","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"5933","DOI":"10.1038\/s41388-019-0866-7","article-title":"Craf mutations in lung cancer can be oncogenic and predict sensitivity to combined type ii raf and mek inhibition","volume":"38","author":"Noeparast","year":"2019","journal-title":"Oncogene"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1158\/1535-7163.MCT-05-0145","article-title":"Braf status and mitogen-activated protein\/extracellular signal-regulated kinase kinase 1\/2 activity indicate sensitivity of melanoma cells to anthrax lethal toxin","volume":"4","author":"Urieto","year":"2005","journal-title":"Mol. Cancer Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ccr.2012.01.004","article-title":"Tem8\/antxr1 blockade inhibits pathological angiogenesis and potentiates tumoricidal responses against multiple cancer types","volume":"21","author":"Chaudhary","year":"2012","journal-title":"Cancer Cell"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.taap.2014.06.010","article-title":"Comparative toxicity and efficacy of engineered anthrax lethal toxin variants with broad anti-tumor activities","volume":"279","author":"Peters","year":"2014","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"9402","DOI":"10.1074\/jbc.M211262200","article-title":"Anthrax lethal factor proteolysis and inactivation of mapk kinase","volume":"278","author":"Chopra","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1126\/science.280.5364.734","article-title":"Proteolytic inactivation of map-kinase-kinase by anthrax lethal factor","volume":"280","author":"Duesbery","year":"1998","journal-title":"Science"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0006-291X(02)00227-9","article-title":"Lethal toxin of bacillus anthracis causes apoptosis of macrophages","volume":"293","author":"Popov","year":"2002","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1462-5822.2004.00458.x","article-title":"Differentiation of human monocytic cell lines confers susceptibility to bacillus anthracis lethal toxin","volume":"7","author":"Kassam","year":"2005","journal-title":"Cell Microbiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.4049\/jimmunol.1400420","article-title":"Hdac8-mediated epigenetic reprogramming plays a key role in resistance to anthrax lethal toxin-induced pyroptosis in macrophages","volume":"193","author":"Ha","year":"2014","journal-title":"J. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Ha, S.D., Cho, W., and Kim, S.O. (2017). Hdac8 prevents anthrax lethal toxin-induced cell cycle arrest through silencing pten in human monocytic thp-1 cells. Toxins, 9.","DOI":"10.3390\/toxins9050162"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1158\/2159-8290.CD-14-0856","article-title":"Pi3\u2019-kinase inhibition forestalls the onset of mek1\/2 inhibitor resistance in braf-mutated melanoma","volume":"5","author":"Deuker","year":"2015","journal-title":"Cancer Discov."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ygyno.2015.04.028","article-title":"Dual blockade of pi3k\/akt\/mtor (nvp-bez235) and ras\/raf\/mek (azd6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas nvp-bez235 reduces tumor growth in the corresponding xenograft models","volume":"138","author":"Schrauwen","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ccr.2010.11.023","article-title":"Acquired resistance to braf inhibitors mediated by a raf kinase switch in melanoma can be overcome by cotargeting mek and igf-1r\/pi3k","volume":"18","author":"Villanueva","year":"2010","journal-title":"Cancer Cell"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1158\/0008-5472.CAN-19-0040","article-title":"Hdac8 regulates a stress response pathway in melanoma to mediate escape from braf inhibitor therapy","volume":"79","author":"Emmons","year":"2019","journal-title":"Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10549-006-9392-8","article-title":"Mda-mb-435 cells are derived from m14 melanoma cells--a loss for breast cancer, but a boon for melanoma research","volume":"104","author":"Rae","year":"2007","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the braf gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1158\/2159-8290.CD-11-0341","article-title":"Egfr-mediated re-activation of mapk signaling contributes to insensitivity of braf mutant colorectal cancers to raf inhibition with vemurafenib","volume":"2","author":"Corcoran","year":"2012","journal-title":"Cancer Discov."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1158\/2159-8290.CD-12-0097","article-title":"Braf(l597) mutations in melanoma are associated with sensitivity to mek inhibitors","volume":"2","author":"Dahlman","year":"2012","journal-title":"Cancer Discov."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.critrevonc.2012.11.003","article-title":"Braf mutations in melanoma and colorectal cancer: A single oncogenic mutation with different tumour phenotypes and clinical implications","volume":"87","author":"Sclafani","year":"2013","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1042\/bj3520739","article-title":"Susceptibility of mitogen-activated protein kinase kinase family members to proteolysis by anthrax lethal factor","volume":"352 Pt. 3","author":"Vitale","year":"2000","journal-title":"Biochem. J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.18632\/oncotarget.659","article-title":"Ras\/raf\/mek\/erk and pi3k\/pten\/akt\/mtor cascade inhibitors: How mutations can result in therapy resistance and how to overcome resistance","volume":"3","author":"McCubrey","year":"2012","journal-title":"Oncotarget"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"36230","DOI":"10.1074\/jbc.M707622200","article-title":"Critical role of the phosphatidylinositol 3-kinase\/akt\/glycogen synthase kinase-3 signaling pathway in recovery from anthrax lethal toxin-induced cell cycle arrest and mek cleavage in macrophages","volume":"282","author":"Ha","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"467","DOI":"10.18632\/oncotarget.293","article-title":"Phosphorylation of akt: A mutational analysis","volume":"2","author":"Hart","year":"2011","journal-title":"Oncotarget"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1096\/fj.14-259051","article-title":"Pi-plcbeta1b affects akt activation, cyclin e expression, and caspase cleavage, promoting cell survival in pro-b-lymphoblastic cells exposed to oxidative stress","volume":"29","author":"Piazzi","year":"2015","journal-title":"FASEB J."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1002\/ijc.30034","article-title":"Desc1, a novel tumor suppressor, sensitizes cells to apoptosis by downregulating the egfr\/akt pathway in esophageal squamous cell carcinoma","volume":"138","author":"Ng","year":"2016","journal-title":"Int. J. Cancer"},{"key":"ref_30","first-page":"2835","article-title":"Selective inhibition of phosphatidylinositol phospholipase c by cytotoxic ether lipid analogues","volume":"52","author":"Powis","year":"1992","journal-title":"Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/sj.bjc.6603856","article-title":"Human desc1 serine protease confers tumorigenic properties to mdck cells and it is upregulated in tumours of different origin","volume":"97","author":"Viloria","year":"2007","journal-title":"Br. J. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ddtec.2013.12.004","article-title":"Resistance to raf inhibition in cancer","volume":"11","author":"Haarberg","year":"2014","journal-title":"Drug Discov. Today Technol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1158\/0008-5472.CAN-18-2738","article-title":"Akt as a therapeutic target for cancer","volume":"79","author":"Song","year":"2019","journal-title":"Cancer Res."},{"key":"ref_34","first-page":"657","article-title":"Phosphorylation of glycogen synthase kinase-3 beta at serine 9 confers cisplatin resistance in ovarian cancer cells","volume":"31","author":"Cai","year":"2007","journal-title":"Int. J. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/ni.3130","article-title":"The kinase jnk2 promotes stress-induced mitophagy by targeting the small mitochondrial form of the tumor suppressor arf for degradation","volume":"16","author":"Zhang","year":"2015","journal-title":"Nat. Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Duda, P., Akula, S.M., Abrams, S.L., Steelman, L.S., Martelli, A.M., Cocco, L., Ratti, S., Candido, S., Libra, M., and Montalto, G. (2020). Targeting gsk3 and associated signaling pathways involved in cancer. Cells, 9.","DOI":"10.3390\/cells9051110"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/978-94-007-3012-0_3","article-title":"The phospholipase c isozymes and their regulation","volume":"58","author":"Gresset","year":"2012","journal-title":"Subcell Biochem."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1074\/mcp.M113.029686","article-title":"Phosphoinositide-specific phospholipase c beta 1b (pi-plcbeta1b) interactome: Affinity purification-mass spectrometry analysis of pi-plcbeta1b with nuclear protein","volume":"12","author":"Piazzi","year":"2013","journal-title":"Mol. Cell Proteom."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.4161\/cc.24806","article-title":"K562 cell proliferation is modulated by plcbeta1 through a pkcalpha-mediated pathway","volume":"12","author":"Poli","year":"2013","journal-title":"Cell Cycle"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1096\/fj.08-121244","article-title":"Involvement of nuclear plcbeta1 in lamin b1 phosphorylation and g2\/m cell cycle progression","volume":"23","author":"Fiume","year":"2009","journal-title":"FASEB J."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S0024-3205(00)00677-9","article-title":"Overexpression of phospholipase cbeta-1 protects nih3t3 cells from oxidative stress-induced cell death","volume":"67","author":"Lee","year":"2000","journal-title":"Life Sci."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/nature12688","article-title":"A melanocyte lineage program confers resistance to map kinase pathway inhibition","volume":"504","author":"Johannessen","year":"2013","journal-title":"Nature"},{"key":"ref_43","first-page":"1697","article-title":"Up-regulated expression of phospholipase c, beta1 is associated with tumor cell proliferation and poor prognosis in hepatocellular carcinoma","volume":"9","author":"Li","year":"2016","journal-title":"Onco. Targets Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"112219","DOI":"10.1016\/j.yexcr.2020.112219","article-title":"Exportin-5 sumoylation promotes hepatocellular carcinoma progression","volume":"395","author":"Lin","year":"2020","journal-title":"Exp. Cell Res."},{"key":"ref_45","first-page":"1","article-title":"Distinct prognostic values of phospholipase c beta family members for non-small cell lung carcinoma","volume":"2019","author":"Zhang","year":"2019","journal-title":"Biomed. Res. Int."},{"key":"ref_46","first-page":"121","article-title":"Microrna-124 inhibits colorectal cancer cell proliferation and suppresses tumor growth by interacting with plcb1 and regulating wnt\/beta-catenin signaling pathway","volume":"23","author":"Lu","year":"2019","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Wang, Q., Ye, J., Fang, D., Lv, L., Wu, W., Shi, D., Li, Y., Yang, L., Bian, X., and Wu, J. (2020). Multi-omic profiling reveals associations between the gut mucosal microbiome, the metabolome, and host DNA methylation associated gene expression in patients with colorectal cancer. BMC Microbiol., 20.","DOI":"10.1186\/s12866-020-01762-2"},{"key":"ref_48","first-page":"403","article-title":"Pi-plcbeta1 gene copy number alterations in breast cancer","volume":"27","author":"Molinari","year":"2012","journal-title":"Oncol Rep."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e384","DOI":"10.1200\/JCO.2010.28.6971","article-title":"Phosphoinositide phospholipase cbeta1 (pi-plcbeta1) gene in myelodysplastic syndromes and cytogenetically normal acute myeloid leukemia: Not a deletion, but increased pi-plcbeta1 expression is an independent prognostic factor","volume":"28","author":"Damm","year":"2010","journal-title":"J. Clin. Oncol"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1054\/bjoc.2000.1586","article-title":"Differential expression of a novel serine protease homologue in squamous cell carcinoma of the head and neck","volume":"84","author":"Lang","year":"2001","journal-title":"Br. J. Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1442-2050.2009.01008.x","article-title":"Identification of some human genes oppositely regulated during esophageal squamous cell carcinoma formation and human embryonic esophagus development","volume":"23","author":"Zinovyeva","year":"2010","journal-title":"Dis. Esophagus"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13046-018-0724-4","article-title":"Lncrna-tusc7\/mir-224 affected chemotherapy resistance of esophageal squamous cell carcinoma by competitively regulating desc1","volume":"37","author":"Chang","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0959-437X(03)00015-7","article-title":"Collaborative spirit of histone deacetylases in regulating chromatin structure and gene expression","volume":"13","author":"Yang","year":"2003","journal-title":"Curr. Opin. Genet. Dev."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.tips.2015.04.013","article-title":"Hdac8: A multifaceted target for therapeutic interventions","volume":"36","author":"Chakrabarti","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_55","first-page":"2941","article-title":"Mir-423-5p inhibits the proliferation and metastasis of glioblastoma cells by targeting phospholipase c beta 1","volume":"12","author":"Zhao","year":"2019","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ejphar.2017.02.035","article-title":"Targeted inhibition of hdac8 increases the doxorubicin sensitivity of neuroblastoma cells via up regulation of mir-137","volume":"802","author":"Zhao","year":"2017","journal-title":"Eur. J. Pharmacol."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/10\/5\/1101\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:57:05Z","timestamp":1760162225000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/10\/5\/1101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,4]]},"references-count":56,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,5]]}},"alternative-id":["cells10051101"],"URL":"https:\/\/doi.org\/10.3390\/cells10051101","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,4]]}}}